HPC
REGN icon

Hobart Private Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Hobart Private Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$312K – 154
2020
Q2 		$312K Sell
500
-251
-33% -$142K 0.18% 130
2020
Q1 		$367K Buy
+751
New +$310K 0.25% 102

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hobart Private Capital's REGN Position: Q3 2020 in Review

Hobart Private Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 500 shares — an estimated $312K sold.

Hobart Private Capital first reported a position in REGN in Q1 2020 and held it in 2 quarters. The position peaked at $367K in Q1 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Hobart Private Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Hobart Private Capital sold 500 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $312K.
  • Hobart Private Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Hobart Private Capital's Regeneron Pharmaceuticals position peaked at $367K in Q1 2020.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Hobart Private Capital's 13F filing for Q3 2020, filed 11 Mar 2024.